您要查找的是不是:
- HBeAg seroconversion at the end of1 year was29% for combination,18% for lamivudine,19% for interferon and4% in placebo. 在临床应用中,拉米夫啶和干扰素(拉米夫啶联用或不与拉米夫啶联用)显示了令人振奋的效果。
- It is still limited to a specific group of patients who have a likelihood of HBeAg seroconversion. 尽可能抵制降低剂量的意愿,这很好解决。
- Thus in Asian patients, HBeAg seroconversion is not a good endpoint for efficacy of treatment. 因而对与亚洲病人,HBeAg血清转换并不是治疗的好的有效终点。
- HBeAg seroconversion at the end of 1 year was 29% for combination, 18% for lamivudine, 19% for interferon and 4% in placebo. 治疗一年后,HBEAG血清转换情况为:联合治疗为29%25,拉米夫啶为18%25,干扰素为19%25,安慰组为4%25。
- In an ongoing follow-up of 3214 Chinese patients at Queen Mary Hospital, the median age of HBeAg seroconversion was 34.6 years. 在一项进行中的3214个中国病人的随访中,HBeAg血清转换的中值为34。6岁。
- Higher baseline ALT,lower baseline HBV DNA levels and the HBeAg decline more than 50% at the early stage of treatment(with EVR) are significant predictors of HBeAg seroconversion for Lamivudine treatment. 治疗前,较高的ALT水平、较低的HBVDNA定量值及出现早期病毒应答是影响拉米夫定治疗慢性乙肝疗效的主要因素。
- The development of cirrhosis related complications and HCC was unrelated to precore mutations, but was probably due to the persistence of significant viremia after HBeAg seroconversion. 最后,有伴有和不伴有并发症的病人中前C区变异的发生率无差异。
- When in HBeAg positive chronic hepatitis B patients with nucleoside analogous antiviral therapy, there are two target as HBV DNA decline or HBeAg seroconversion, which target is more important? HBeAg阳性的慢乙肝患者使用核苷类药物进行抗病毒治疗,有两个目标需要达到,病毒含量下降或者HBeAg血清阴转,哪一个更加重要?
- We can also predict the HBeAg of patients to be seroconversion or not.According to amino acids sequence of virus in the first sampled blood, we can predict the trend of HBeAg seroconversion. 并且由病人抽血第一时间点的病毒胺基酸序列,归纳出可判定病人是否有走入血清转换的或已达血清转换的趋势之准则。
- Clinical investigation on occurrence of HBeAg seroconversion during continuous Lamivudine therapy after emergence of HBV YMDD mutation YMDD变异后继续应用拉米夫定发生血清转换的临床研究
- HBeAg seroconversion 乙型肝炎病毒e抗原血清转换
- BCP mutation may impair HBeAg expression. BCP双突变对HBeAg的表达有一定影响 ;
- This process is manifested as seroconversion. 这个过程表现为血清转化。
- Long-delayed seroconversion is urban myth! (长期延后的血清阳转是一个神话!
- We have very few HBeAg positive patients here in Europe. 在欧洲,我们e抗原阳性的患者很少。
- For HBeAg negative patient, the relapse rate is quite high. HBeAg阴性的患者复发率相当高。
- Is there any seroconversion lasting more than a year and a half ? 有没有一年半后血清转阳的个案?
- The presence of HBEAG is indicative of ongoing hepatitis B infection. 出现HBEAG阳性表示正在进行的乙肝感染。
- It is found that the EtOH extract has inhibiting effect on the HBsAg and HBeAg. 经生物活性筛选,首次发现椭圆叶花锚的乙醇提取物对HBsAg和HBeAg有一定的抑制作用。
- Result The rate of seroconversion in various subpopulations of these 1701 vaccinated individuals was in the ... 结论注射狂犬疫苗的人群抗体阳性率仍未能达到100%25,对结果阴性者应及时补种疫苗。